Drug
Fodipir clinical trials
Also written PledOx.
- studies test it
- 11
- open now
- 1
- in phase 3
- 2
- first study started
- 2008
Keep track of what changes. Save the fodipir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 4
Egetis Therapeutics (7) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · IC TARGETS AS (1) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses fodipir is read from its arms, and is right about nine times in ten.
Testing it · 11
- Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant EpilepsyRecruitingPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT02531880Written as Mangafodipir
- Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.CompletedPhase 2IC TARGETS ASNCT06731738Written as Mangafodipir trisodium injection
- Protective Effect of Mangafodipir Against Oxaliplatin NeurotoxicityCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT00727922Written as Mangafodipir
- Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisCompletedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT01326715Written as Mangafodipir (Teslascan)
- Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal CancerTerminatedPhase 3Egetis TherapeuticsNCT04034355Written as Calmangafodipir (5 µmol/kg)
- Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)TerminatedPhase 3Egetis TherapeuticsNCT03654729Written as Calmangafodipir (2 µmol/kg)
- PP100-01 (Calmangafodipir) for Overdose of ParacetamolCompletedPhase 1Egetis TherapeuticsNCT03177395Written as PP100-01 (calmangafodipir)
- A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal CancerCompletedPhase 1/2Egetis TherapeuticsNCT01619423Written as PledOx (2 µmol/kg)
- SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian SubjectsCompletedPhase 1Egetis TherapeuticsNCT03430999Written as Calmangafodipir
- Mangafodipir as an Adjunct to Percutaneous Coronary InterventionCompletedPhase 2Egetis TherapeuticsNCT00966563Written as Mangafodipir
- Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' CCompletedPhase 2Egetis TherapeuticsNCT00671996Written as Mangafodipir
Codes
What other systems call fodipir · ClinicalTrials.gg INT003441
- MeSH (NLM) C060076N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acidConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P28BIW0UTBFODIPIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27286033fodipirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174827FodipirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C060076 | N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P28BIW0UTB | FODIPIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27286033 | fodipir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174827 | Fodipir | One source FDA |
Also registered as calmangafodipir (UNII N0JZU0WGU5), mangafodipir (UNII N02W67RKJS · RxNorm 236987) and mangafodipir trisodium (UNII 129FW80TG4 · RxNorm 221119).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.